Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Huadong Medicine Co. Ltd.
Headquarters: Hangzhou, China
Website: http://www.eastchinapharm.co...
Year Founded: 1993
Status: Public
Industry Sector: HealthTechnology
CEO: Liang Lü
Number Of Employees: 16,969
Enterprise Value: $10,202,781,805
PE Ratio: 19.33
Exchange/Ticker 1: SZSE:000963
Exchange/Ticker 2: N/A
Latest Market Cap: $8,597,120,225
BioCentury | Dec 6, 2023
Data Byte
After Carmot deal, seven clinical oral GLP-1s remain unpartnered
A look at the oral GLP-1 pipeline
BioCentury | Aug 31, 2023
Finance
Aug. 31 Quick Takes: Sage downsizes, reveals executive departures
Plus: CCM launches with $25M+ and updates from Kangpu, Clock Bio, MC2, Huadong and RabPharma
BioCentury | Aug 10, 2023
Regulation
Aug. 10 Quick Takes: FDA approves Janssen’s first-in-class bispecific for MM
Plus: Arcutis out-licenses Asia rights to skin drug and financings for Tango, Merus, Jinlan Gene Technology
BioCentury | Jan 18, 2023
Regulation
Jan. 17 Quick Takes: Moderna now in RSV vaccine regulatory race
Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more
BioCentury | Apr 27, 2022
Emerging Company Profile
Ashvattha branches out with $69M series B for dendrimer therapies
JHU spinout advancing COVID-19, ophthalmic programs based on hydroxyl dendrimer platform
BioCentury | Mar 1, 2022
Deals
Feb. 28 Quick Takes: Heidelberg shares jump as Huadong takes stake
Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more
BioCentury | Feb 23, 2022
Product Development
Feb. 22 Quick Takes: Enhertu meets mark in breast cancer subgroup
Plus updates from BeiGene, Takeda, Code, Kiniksa, Hangzhou, Homology and more
BioCentury | Dec 1, 2021
Product Development
ImmunoGen ADC hits mark in ovarian cancer subgroup, heads for FDA
Following 2019 miss in Phase III trial, ImmunoGen’s mirvetuximab finds success in narrower population
BioCentury | Oct 28, 2020
Product Development
Data Byte: FOLR1 pipeline for cancer
At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.
BioCentury | Oct 19, 2020
Deals
ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC
ImmunoGen has been signaling for months that it would soon strike a licensing deal in China for its lead antibody-drug conjugate. On Monday, the biotech said Huadong will gain the program’s
Items per page:
1 - 10 of 10